The GSK DERMA study evaluated the efficacy and safety of the MAGE-A3 cancer immunotherapeutic, when compared to placebo, in MAGE-A3 positive patients (those whose tumor shows expression of the MAGE-A3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback